CN107094756A - A kind of breast cancer cell frozen stock solutions of high viability MCF 7 - Google Patents
A kind of breast cancer cell frozen stock solutions of high viability MCF 7 Download PDFInfo
- Publication number
- CN107094756A CN107094756A CN201710527399.2A CN201710527399A CN107094756A CN 107094756 A CN107094756 A CN 107094756A CN 201710527399 A CN201710527399 A CN 201710527399A CN 107094756 A CN107094756 A CN 107094756A
- Authority
- CN
- China
- Prior art keywords
- parts
- breast cancer
- mcf
- frozen stock
- stock solutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of breast cancer cell frozen stock solutions of high viability MCF 7, including dimethyl sulfoxide (DMSO), hydroxymethyl starch, sorbose, vitamin C, 50% hypertonic glucose, propane diols, (S) () 1 (base of 4 fluorine isoquinolin 5）The phenodiazine cycloheptane of 2 methyl of sulfonyl 1,4 and basal medium.The special frozen stock solution of the breast cancer cells of MCF 7 of the present invention, component is reasonable, it is nutritious, the damage to cell can also be substantially reduced while the nutrition of rest cell is ensured, improve the survival rate of freeze-stored cell, and good state is also kept in terms of propagation, the correlative study of comparative study etc. can be conveniently carried out applied to the growth in situ of breast cancer, angiogenesis and with the high metastatic cell of other breast cancer.
Description
Technical field
The invention belongs to biological technology application, in particular it relates to which a kind of high viability MCF-7 breast cancer cells freeze
Liquid.
Background technology
Breast cancer is the most common cancer of women, mainly includes duct carcinoma and lobular carcinoma.U.S. CA in 2016（A Cancer
Journal for Clinicians）The recent statistics data display of announcement, the U.S. is expected will there is 420840 women in 2016
Suffer from breast cancer, account for the 38% of women de novo malignancy, occupy the female malignant incidence of disease first, and death toll will reach
52930.More seriously global breast cancer incidence increases year by year.
Cell culture medium is a biological important technology with healthy Related Research Domain.With the rapid hair of life science
Exhibition, current cell culture turns into the important base of the disciplinary studies such as cell biology, molecular biology, science of heredity and immunology
Plinth.In order to further investigated cell vegetative activity rule, have the pathology of related disorders and the pharmacology of medicine（Toxicity）Mechanism, exploitation tool
There are different targetedly cell culture processes significant.
Wherein, MCF-7 breast cancer cells are as the low metastatic breast cancer cell of humanized, be usually used in breast cancer orthotopic growth,
The in vivo and in vitro of the breast cancer such as angiogenesis.In addition, MCF-7 breast cancer cells can also be with the high metastatic cell of other breast cancer
Carry out comparative study.However, histocyte culture multiplication technique is used with increasing in research process, by MCF-7 breasts
Adenocarcinoma cell carries out preserving several months, several years, many decades even centuries for a long time using low temperature, once need, can be at any time to institute
The cell of preservation is recovered, and recovers its complete morphosis and biological characteristics, is tested for life science.
The content of the invention
Goal of the invention：The invention provides a kind of high viability MCF-7 breast cancer cell frozen stock solutions, for a variety of people sources with
And the culture of non-human archeocyte.
Technical scheme：The invention provides a kind of high viability MCF-7 breast cancer cell frozen stock solutions, by weight part,
Including following components：It is 5-15 parts of dimethyl sulfoxide (DMSO), 2-5 parts of hydroxymethyl starch, 3-12 parts of sorbose, 1-4 parts of vitamin C, 50% high
Ooze 0.8-3 parts of glucose, 1-1.5 parts of propane diols, (S)-(-) -1- (4- fluorine isoquinolin -5- bases）Sulfonyl -2- methyl isophthalic acids, 4- bis-
80-90 parts of 0.3-3 parts of azo-cycle heptane and basal medium.The special frozen stock solution of MCF-7 breast cancer cells of the present invention, component
Rationally, it is nutritious, wherein, 50% hypertonic glucose is permeability protection liquid, and (S)-(-) -1- (4- fluorine isoquinolin -5- bases)
Sulfonyl -2- methyl isophthalic acids, 4- phenodiazine cycloheptane then suppresses cellular activity and gene expression, and ascorbic good in oxidation resistance is being protected
The damage to cell can also be substantially reduced while the nutrition for demonstrate,proving rest cell, improve the survival rate of freeze-stored cell, and
Good state is also kept in terms of propagation, can be conveniently applied to the growth in situ of breast cancer, angiogenesis and newborn with other
The high metastatic cell of gland cancer carries out the correlative study of comparative study etc..
Further, above-mentioned high viability MCF-7 breast cancer cell frozen stock solutions, the basal medium is with components by weight percent
Meter, including following components：82-88 parts of glucose, 12-25 parts of sodium acid carbonate, 10-16 parts of Sodium Pyruvate, transferrins 3-8
Part, 35-45 parts of potassium chloride, 6-10 parts of anhydrous magnesium sulfate, 70-78 parts of sodium chloride, 5-8 parts of lithium chloride, AMSP
10-14 parts, 0.3-0.5 parts of folic acid, 0.8-1.2 parts of inositol, 0.3-0.6 parts of niacinamide, 25-35 parts of anhydrous calcium chloride, ferric nitrate
0.2-0.4 parts, 6-8 parts of succinic acid, 12-16 parts of sodium succinate, 0.3-0.6 parts of D-VB5 calcium, 0.6-0.8 parts of choline tartrate,
0.1-0.3 parts of riboflavin, 0.2-0.4 parts of thiamine hydrochloride, 0.3-0.5 parts of pyridoxine hydrochloride, 4-（2- ethoxys）- 1- piperazine second
0.3-0.6 parts of sulfonic acid, 1-1.5 parts of linseed oil, 0.8-1.6 parts of polyglycerol fatty acid ester, phenol red sodium 1-1.3 parts and 100 parts of deionized water.
Further, above-mentioned high viability MCF-7 breast cancer cell frozen stock solutions, the basal medium also includes 3-8
Part amino acid, the amino acid is by weight part, composed of the following components：5-10 parts of L- R-genes, L- hydrochloric acid Guang ammonia
Sour 3-8 parts, 3-6 parts of Serine, 1-5 parts of glycine, 4-6 parts of L- histidine monohydrochlorides, 8-20 parts of ILE, the bright ammonia of L-
Sour 7-18 parts, 10-20 parts of LYS, 1-6 parts of METHIONINE, 2-8 parts of L-phenylalanine, 5-15 parts of L-threonine,
8-12 parts of 1-3 parts of L-Trp, 5-9 parts of TYR and Valine.
Further, above-mentioned high viability MCF-7 breast cancer cell frozen stock solutions, the basal medium also includes 2-5
Part confactor, the confactor is by weight part, composed of the following components：3-8 parts of insulin-like growth factor, interleukin
6 2-5 parts, 1-4 parts of IL-10,3-6 parts of interleukin 12,2-10 parts, GM-CSF1-5 parts of TNF-β.Basal medium component
Rationally, it is nutritious, nutriment when MDA-MB-231 breast cancer cells freeze can be improved, it is ensured that the work of freeze-stored cell
Property.
Further, above-mentioned high viability MCF-7 breast cancer cell frozen stock solutions, the basal medium also includes volume
Hyclone than 10-30%.Can be as needed, further increase hyclone, improve the survival rate of freeze-stored cell, keep
Cytoactive.
Further, above-mentioned high viability MCF-7 breast cancer cell frozen stock solutions, the basal medium is with components by weight percent
Meter, in addition to 0.006 part of penicillin and 0.01 part of streptomysin.Freeze-stored cell can be effectively prevented to be contaminated.
Further, above-mentioned high viability MCF-7 breast cancer cell frozen stock solutions, the penicillin is selected from 10000U/ml,
The streptomysin is selected from 10000 μ g/ml.Penicillin and streptomysin activity are good, and effect is good.
Beneficial effect：The special frozen stock solution of MCF-7 breast cancer cells of the present invention, component is rationally, nutritious, is protecting
The damage to cell can also be substantially reduced while the nutrition for demonstrate,proving rest cell, improve the survival rate of freeze-stored cell, and
Good state is also kept in terms of propagation, can be conveniently applied to the growth in situ of breast cancer, angiogenesis and newborn with other
The high metastatic cell of gland cancer carries out the correlative study of comparative study etc..
Embodiment
Below will be by several specific embodiments, the present invention is furture elucidated, these embodiments simply to illustrate that problem,
It is not a kind of limitation.
Embodiment 1
A kind of high viability MCF-7 breast cancer cell frozen stock solutions, by weight part, including following components：Dimethyl sulfoxide (DMSO) 5
Part, 2 parts of hydroxymethyl starch, 3 parts of sorbose, 1 part of vitamin C, 0.8 part of 50% hypertonic glucose, 1 part of propane diols, (S)-(-) -1-
(4- fluorine isoquinolin -5- bases）80 parts of sulfonyl -2- methyl isophthalic acids, 0.3 part of 4- phenodiazines cycloheptane and basal medium.
Wherein, the basal medium by weight part, including following components：82 parts of glucose, sodium acid carbonate 12
Part, 10 parts of Sodium Pyruvate, 3 parts of transferrins, 35 parts of potassium chloride, 6 parts of anhydrous magnesium sulfate, 70 parts of sodium chloride, 5 parts of lithium chloride, nothing
10 parts of water sodium dihydrogen phosphate, 0.3 part of folic acid, 0.8 part of inositol, 0.3 part of niacinamide, 25 parts of anhydrous calcium chloride, 0.2 part of ferric nitrate,
6 parts of succinic acid, 12 parts of sodium succinate, 0.3 part of D-VB5 calcium, 0.6 part of choline tartrate, 0.1 part of riboflavin, thiamine hydrochloride 0.2
Part, 0.3 part of pyridoxine hydrochloride, 4-（2- ethoxys）0.3 part of -1- piperazine ethanesulfonic acids, 1 part of linseed oil, 0.8 part of polyglycerol fatty acid ester,
100 parts of 1 part of phenol red sodium and deionized water.
In addition, the basal medium also includes 3 parts of amino acid, the amino acid by weight part, by following components group
Into：5 parts of L- R-genes, 3 parts of L- hydrochloric acid cystine, 3 parts of Serine, 1 part of glycine, 4 parts of L- histidine monohydrochlorides,
8 parts of ILE, 7 parts of L-Leu, 10 parts of LYS, 1 part of METHIONINE, 2 parts of L-phenylalanine, L- Soviet Unions ammonia
8 parts of 5 parts of acid, 1 part of L-Trp, 5 parts of TYR and Valine.
Again, the basal medium also includes 2 parts of confactors, the confactor by weight part, by with the following group
It is grouped into：3 parts of insulin-like growth factor, 2 parts of interleukin 6,1 part of IL-10,3 parts of interleukin 12,2 parts of TNF-β, GM-
1 part of CSF.
Further, the basal medium also includes the hyclone of volume ratio 10%.In addition, the basal medium
By weight part, in addition to 0.006 part of penicillin and 0.01 part of streptomysin.Also, the penicillin is selected from 10000U/
Ml, the streptomysin is selected from 10000 μ g/ml.
Embodiment 2
A kind of high viability MCF-7 breast cancer cell frozen stock solutions, by weight part, including following components：Dimethyl sulfoxide (DMSO) 15
Part, 5 parts of hydroxymethyl starch, 12 parts of sorbose, 4 parts of vitamin C, 3 parts of 50% hypertonic glucose, 1.5 parts of propane diols, (S)-(-)-
1- (4- fluorine isoquinolin -5- bases）90 parts of sulfonyl -2- methyl isophthalic acids, 3 parts of 4- phenodiazines cycloheptane and basal medium.
Wherein, the basal medium by weight part, including following components：88 parts of glucose, sodium acid carbonate 25
Part, 16 parts of Sodium Pyruvate, 8 parts of transferrins, 45 parts of potassium chloride, 10 parts of anhydrous magnesium sulfate, 78 parts of sodium chloride, 8 parts of lithium chloride, nothing
14 parts of water sodium dihydrogen phosphate, 0.5 part of folic acid, 1.2 parts of inositol, 0.6 part of niacinamide, 35 parts of anhydrous calcium chloride, 0.4 part of ferric nitrate,
8 parts of succinic acid, 16 parts of sodium succinate, 0.6 part of D-VB5 calcium, 0.8 part of choline tartrate, 0.3 part of riboflavin, thiamine hydrochloride 0.4
Part, 0.5 part of pyridoxine hydrochloride, 4-（2- ethoxys）0.6 part of -1- piperazine ethanesulfonic acids, 1.5 parts of linseed oil, polyglycerol fatty acid ester 1.6
100 parts of part, 1.3 parts of phenol red sodium and deionized water.
In addition, the basal medium also includes 8 parts of amino acid, the amino acid by weight part, by following components group
Into：10 parts of L- R-genes, 8 parts of L- hydrochloric acid cystine, 6 parts of Serine, 5 parts of glycine, 6 parts of L- histidine monohydrochlorides,
20 parts of ILE, 18 parts of L-Leu, 20 parts of LYS, 6 parts of METHIONINE, 8 parts of L-phenylalanine, L- Soviet Unions
12 parts of 15 parts of propylhomoserin, 3 parts of L-Trp, 9 parts of TYR and Valine.
Again, the basal medium also includes 5 parts of confactors, the confactor by weight part, by with the following group
It is grouped into：8 parts of insulin-like growth factor, 5 parts of interleukin 6,4 parts of IL-10,6 parts of interleukin 12,10 parts of TNF-β, GM-
5 parts of CSF.
Further, the basal medium also includes the hyclone of volume ratio 30%.In addition, the basal medium
By weight part, in addition to 0.006 part of penicillin and 0.01 part of streptomysin.Also, the penicillin is selected from 10000U/
Ml, the streptomysin is selected from 10000 μ g/ml.
Embodiment 3
A kind of high viability MCF-7 breast cancer cell frozen stock solutions, by weight part, including following components：Dimethyl sulfoxide (DMSO) 12
Part, 3 parts of hydroxymethyl starch, 8 parts of sorbose, Catergen part, 2 parts of 50% hypertonic glucose, 1.2 parts of propane diols, (S)-(-) -1-
(4- fluorine isoquinolin -5- bases）85 parts of sulfonyl -2- methyl isophthalic acids, 0.3-3 parts of 4- phenodiazine cycloheptane and basal medium.
Wherein, the basal medium by weight part, including following components：86 parts of glucose, sodium acid carbonate 18
Part, 12 parts of Sodium Pyruvate, 6 parts of transferrins, 40 parts of potassium chloride, 8 parts of anhydrous magnesium sulfate, 75 parts of sodium chloride, 6 parts of lithium chloride, nothing
12 parts of water sodium dihydrogen phosphate, 0.4 part of folic acid, 1 part of inositol, 0.5 part of niacinamide, 30 parts of anhydrous calcium chloride, 0.3 part of ferric nitrate, fourth
7 parts of diacid, 14 parts of sodium succinate, 0.5 part of D-VB5 calcium, 0.7 part of choline tartrate, 0.2 part of riboflavin, thiamine hydrochloride 0.3
Part, 0.4 part of pyridoxine hydrochloride, 4-（2- ethoxys）0.5 part of -1- piperazine ethanesulfonic acids, 1.2 parts of linseed oil, polyglycerol fatty acid ester 1.2
100 parts of part, 1.2 parts of phenol red sodium and deionized water.
In addition, the basal medium also includes 5 parts of amino acid, the amino acid by weight part, by following components group
Into：8 parts of L- R-genes, 6 parts of L- hydrochloric acid cystine, 5 parts of Serine, 4 parts of glycine, 5 parts of L- histidine monohydrochlorides, L-
12 parts of isoleucine, 10 parts of L-Leu, 16 parts of LYS, 3 parts of METHIONINE, 6 parts of L-phenylalanine, L- Soviet Unions ammonia
10 parts of 9 parts of acid, 2 parts of L-Trp, 6 parts of TYR and Valine.
Again, the basal medium also includes 3 parts of confactors, the confactor by weight part, by with the following group
It is grouped into：4 parts of insulin-like growth factor, 4 parts of interleukin 6,3 parts of IL-10,5 parts of interleukin 12,8 parts of TNF-β, GM-
CSF3 parts.
Further, the basal medium also includes the hyclone of volume ratio 20%.In addition, the basal medium
By weight part, in addition to 0.006 part of penicillin and 0.01 part of streptomysin.Also, the penicillin is selected from 10000U/
Ml, the streptomysin is selected from 10000 μ g/ml.
Embodiment 4
A kind of high viability MCF-7 breast cancer cell frozen stock solutions, by weight part, including following components：Dimethyl sulfoxide (DMSO) 5
Part, 2 parts of hydroxymethyl starch, 12 parts of sorbose, 4 parts of vitamin C, 2 parts of 50% hypertonic glucose, 1.2 parts of propane diols, (S)-(-)-
1- (4- fluorine isoquinolin -5- bases）90 parts of sulfonyl -2- methyl isophthalic acids, 1.5 parts of 4- phenodiazines cycloheptane and basal medium.
Wherein, the basal medium by weight part, including following components：82 parts of glucose, sodium acid carbonate 25
Part, 16 parts of Sodium Pyruvate, 5 parts of transferrins, 40 parts of potassium chloride, 6 parts of anhydrous magnesium sulfate, 78 parts of sodium chloride, 6 parts of lithium chloride, nothing
12 parts of water sodium dihydrogen phosphate, 0.4 part of folic acid, 1.2 parts of inositol, 0.3 part of niacinamide, 28 parts of anhydrous calcium chloride, 0.2 part of ferric nitrate,
8 parts of succinic acid, 12 parts of sodium succinate, 0.6 part of D-VB5 calcium, 0.8 part of choline tartrate, 0.1 part of riboflavin, thiamine hydrochloride 0.4
Part, 0.3 part of pyridoxine hydrochloride, 4-（2- ethoxys）0.6 part of -1- piperazine ethanesulfonic acids, 1.2 parts of linseed oil, polyglycerol fatty acid ester 0.8
100 parts of part, 1.3 parts of phenol red sodium and deionized water.
In addition, the basal medium also includes 5 parts of amino acid, the amino acid by weight part, by following components group
Into：5 parts of L- R-genes, 8 parts of L- hydrochloric acid cystine, 3 parts of Serine, 4 parts of glycine, 5 parts of L- histidine monohydrochlorides,
12 parts of ILE, 7 parts of L-Leu, 10 parts of LYS, 6 parts of METHIONINE, 8 parts of L-phenylalanine, L- Soviet Unions
8 parts of 9 parts of propylhomoserin, 2 parts of L-Trp, 8 parts of TYR and Valine.
Again, the basal medium also includes 2 parts of confactors, the confactor by weight part, by with the following group
It is grouped into：3 parts of insulin-like growth factor, 5 parts of interleukin 6,3 parts of IL-10,5 parts of interleukin 12,8 parts of TNF-β, GM-
CSF5 parts.
Further, the basal medium also includes the hyclone of volume ratio 15%.In addition, the basal medium
By weight part, in addition to 0.006 part of penicillin and 0.01 part of streptomysin.Also, the penicillin is selected from 10000U/
Ml, the streptomysin is selected from 10000 μ g/ml.
The cell that embodiment 1-4 is frozen take respectively freeze after 3 months, 6 months, 9 months, 12 months, 18 months and
The freeze-stored cell of 24 months is recovered, and cell survival rate is measured, and cell survival rate is more than 90%.
Described above is only several embodiments of invention, it is noted that for those skilled in the art
For, on the premise of inventive principle is not departed from, some improvement can also be made, these improvement also should be regarded as the protection of the present invention
Scope.
Claims (7)
1. a kind of high viability MCF-7 breast cancer cell frozen stock solutions, it is characterised in that：By weight part, including following components：
5-15 parts of dimethyl sulfoxide (DMSO), 2-5 parts of hydroxymethyl starch, 3-12 parts of sorbose, 1-4 parts of vitamin C, 50% hypertonic glucose 0.8-3
Part, 1-1.5 parts of propane diols, (S)-(-) -1- (4- fluorine isoquinolin -5- bases）Sulfonyl -2- methyl isophthalic acids, 4- phenodiazine cycloheptane 0.3-3
80-90 parts of part and basal medium.
2. high viability MCF-7 breast cancer cell frozen stock solutions according to claim 1, it is characterised in that：The basis training
Foster base by weight part, including following components：82-88 parts of glucose, 12-25 parts of sodium acid carbonate, Sodium Pyruvate 10-16
Part, 3-8 parts of transferrins, 35-45 parts of potassium chloride, 6-10 parts of anhydrous magnesium sulfate, 70-78 parts of sodium chloride, 5-8 parts of lithium chloride, nothing
10-14 parts of water sodium dihydrogen phosphate, 0.3-0.5 parts of folic acid, 0.8-1.2 parts of inositol, 0.3-0.6 parts of niacinamide, anhydrous calcium chloride
25-35 parts, 0.2-0.4 parts of ferric nitrate, 6-8 parts of succinic acid, 12-16 parts of sodium succinate, 0.3-0.6 parts of D-VB5 calcium, tartaric acid
0.6-0.8 parts of choline, 0.1-0.3 parts of riboflavin, 0.2-0.4 parts of thiamine hydrochloride, 0.3-0.5 parts of pyridoxine hydrochloride, 4-（2- hydroxyls
Ethyl）0.3-0.6 parts of -1- piperazine ethanesulfonic acids, 1-1.5 parts of linseed oil, 0.8-1.6 parts of polyglycerol fatty acid ester, phenol red sodium 1-1.3 parts and
100 parts of deionized water.
3. high viability MCF-7 breast cancer cell frozen stock solutions according to claim 2, it is characterised in that：The basis training
Foster base also includes 3-8 parts of amino acid, and the amino acid is by weight part, composed of the following components：L- R-genes 5-10
Part, 3-8 parts of L- hydrochloric acid cystines, 3-6 parts of Serine, 1-5 parts of glycine, 4-6 parts of L- histidine monohydrochlorides, ILE
8-20 parts, 7-18 parts of L-Leu, 10-20 parts of LYS, 1-6 parts of METHIONINE, 2-8 parts of L-phenylalanine, L-
8-12 parts of 5-15 parts of threonine, 1-3 parts of L-Trp, 5-9 parts of TYR and Valine.
4. the high viability MCF-7 breast cancer cell frozen stock solutions according to Claims 2 or 3, it is characterised in that：The basis
Culture medium also includes 2-5 parts of confactors, and the confactor is by weight part, composed of the following components：Insulin growth
3-8 parts of the factor, 2-5 parts of interleukin 6,1-4 parts of IL-10,3-6 parts of interleukin 12,2-10 parts of TNF-β, GM-CSF1-5
Part.
5. high viability MCF-7 breast cancer cell frozen stock solutions according to claim 4, it is characterised in that：The basis training
Foster base also includes volume ratio 10-30% hyclone.
6. high viability MCF-7 breast cancer cell frozen stock solutions according to claim 5, it is characterised in that：The basis training
Foster base by weight part, in addition to 0.006 part of penicillin and 0.01 part of streptomysin.
7. high viability MCF-7 breast cancer cell frozen stock solutions according to claim 6, it is characterised in that：The penicillin
Selected from 10000U/ml, the streptomysin is selected from 10000 μ g/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710527399.2A CN107094756A (en) | 2017-06-30 | 2017-06-30 | A kind of breast cancer cell frozen stock solutions of high viability MCF 7 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710527399.2A CN107094756A (en) | 2017-06-30 | 2017-06-30 | A kind of breast cancer cell frozen stock solutions of high viability MCF 7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107094756A true CN107094756A (en) | 2017-08-29 |
Family
ID=59664178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710527399.2A Pending CN107094756A (en) | 2017-06-30 | 2017-06-30 | A kind of breast cancer cell frozen stock solutions of high viability MCF 7 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107094756A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107646831A (en) * | 2017-11-13 | 2018-02-02 | 重庆斯德姆生物技术有限公司 | A kind of frozen stock solution for the breast cancer cells of MCF 7 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287513A1 (en) * | 2003-10-30 | 2005-12-29 | Davis Ashley S | Method for preserving intracellular molecular detail |
| CN103891709A (en) * | 2012-12-24 | 2014-07-02 | 深圳先进技术研究院 | Cell cryopreservation liquid and cell cryopreservation method |
-
2017
- 2017-06-30 CN CN201710527399.2A patent/CN107094756A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287513A1 (en) * | 2003-10-30 | 2005-12-29 | Davis Ashley S | Method for preserving intracellular molecular detail |
| CN103891709A (en) * | 2012-12-24 | 2014-07-02 | 深圳先进技术研究院 | Cell cryopreservation liquid and cell cryopreservation method |
Non-Patent Citations (1)
| Title |
|---|
| 陈宁 等: "《酶工程》", 30 June 2011, 中国轻工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107646831A (en) * | 2017-11-13 | 2018-02-02 | 重庆斯德姆生物技术有限公司 | A kind of frozen stock solution for the breast cancer cells of MCF 7 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104663649B (en) | Human oocytes cryoprotective agent | |
| CN103724072B (en) | One plant nutrient liquor | |
| CN107251893A (en) | A kind of novel cell frozen stock solution | |
| CN102648708B (en) | Freezing liquid for embryo or cells and application thereof | |
| Rudd et al. | Eight hours of cold static storage with adenosine and lidocaine (Adenocaine) heart preservation solutions: toward therapeutic suspended animation | |
| Fuhrman | Inhibition of active sodium transport in the isolated frog skin | |
| JP4931035B2 (en) | Anti-freezing solution for cells and tissues and cryopreservation method | |
| CN107094756A (en) | A kind of breast cancer cell frozen stock solutions of high viability MCF 7 | |
| PH12016500909B1 (en) | Solutons for increasing the stability and shelf life of an organ tissue preservation solution | |
| CN107164328A (en) | A kind of method for resuscitation of the breast cancer cells of high stability MCF 7 | |
| CN107258768A (en) | A kind of special frozen stock solution of breast cancer cells of MDA MB 231 | |
| CN107151657A (en) | A kind of method for resuscitation of the breast cancer cells of MCF easily and fast 7 | |
| CN107183011A (en) | A kind of cryopreservation methods of the breast cancer cells of MCF 7 | |
| CN107251894A (en) | A kind of cell freezing method of high viability | |
| CN109122666B (en) | Ready-to-use erythrocyte cryoprotectant for resuscitation and use method | |
| Minami et al. | Creatine kinase and troponin after myocardial preservation using HTK solution (Custoidol) for clinical heart transplantation | |
| CN103329990B (en) | Nanotitanium dioxide-based fruit fresh-keeping composite and fresh keeping method | |
| CN107177554A (en) | A kind of method that breast cancer cells of MCF 7 expand culture | |
| CN102524241A (en) | Additive for freezing storage protective liquid of fish spermatid | |
| Yu et al. | Effects of hypoxia on the gill morphological structure, apoptosis and hypoxia-related gene expression in blunt snout bream (Megalobrama amblycephala) | |
| WO2017101587A1 (en) | Megakaryocyte progenitor cryopreservation liquid and use thereof | |
| CN107211995A (en) | A kind of cryopreservation methods of the breast cancer cells of easily MDA MB 231 | |
| CN107306938A (en) | A kind of Vero cells frozen storing liquids | |
| Khorsandi et al. | The effect of anterograde persufflation on energy charge and hepatocyte function in donation after cardiac death livers unsuitable for transplant | |
| Laptikhovsky | White blood of the Antarctic icefish: Why? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200918 Address after: 1101, room 36, building 2, Huahai Business Plaza, No. 215400 Taiping North Road, Taicang Economic Development Zone, Jiangsu, Suzhou Applicant after: Suzhou Shengdian Enterprise Management Consulting Co.,Ltd. Address before: 215400 Qingdao Road, Taicang Economic Development Zone, Suzhou City, Jiangsu Province Applicant before: SUZHOU CHENGSHENG INFORMATION TECHNOLOGY Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170829 |